Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2014

Open Access 01-12-2014 | Research

Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression

Authors: Tong-peng Xu, Ming-de Huang, Rui Xia, Xin-xin Liu, Ming Sun, Li Yin, Wen-ming Chen, Liang Han, Er-bao Zhang, Rong Kong, Wei De, Yong-qian Shu

Published in: Journal of Hematology & Oncology | Issue 1/2014

Login to get access

Abstract

Background

FENDRR is a long non-coding RNAs (lncRNA) that binds to polycomb repressive complexe 2 (PRC2) to epigenetically regulate the expression of its target gene. The clinical role of FENDRR in carcinomas remains yet to be found.

Method

Real-time polymerase chain reaction (PCR) was used to examine FENDRR expression in gastric cancer cell lines/tissues compared with normal epithelial cells/adjacent non-tumorous tissues. Cell proliferation assays, Wound healing assays, and in vitro and in vivo invasion and migration assays were performed to detect the biological effects of FENDRR in gastric cancer cells. Real-time PCR, western-blot and immunohistochemistry were used to evaluate the mRNA and protein expression of fibronectin1 (FN1). Secreted matrix metalloproteinase (MMP) activities were detected and characterized using gelatin zymography assay.

Results

FENDRR was downregulated in gastric cancer cell lines and cancerous tissues, as compared with normal gastric epithelial cells and adjacent noncancerous tissue samples. Low FENDRR expression was correlated with deeper tumor invasion (p < 0.001), higher tumor stage (p = 0.001), and lymphatic metastasis (p = 0.007). Univariate and multivariate analyses indicated that low FENDRR expression predicted poor prognosis. Histone deacetylation was involved in the downregulation of FENDRR in gastric cancer cells. FENDER overexpression suppressed invasion and migration by gastric cancer cells in vitro, by downregulating FN1 and MMP2/MMP9 expression.

Conclusion

Low expression of the lncRNA FENDRR occurs in gastric cancer and is associated with poor prognosis. Thus, FENDRR plays an important role in the progression and metastasis of gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Moore MA, Attasara P, Khuhaprema T, Le TN, Nguyen TH, Raingsey PP, Sriamporn S, Sriplung H, Srivanatanakul P, Bui DT, Wiangnon S, Sobue T: Cancer epidemiology in mainland South-East Asia - past, present and future. Asian Pac J Cancer Prev. 2010, 11 (Suppl 2): 67-80.PubMed
2.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRefPubMed
3.
Wang XN, Liang H: Some problems in the surgical treatment of gastric cancer. Chin J Cancer. 2010, 29: 369-373. 10.5732/cjc.009.10629.CrossRefPubMed
4.
Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003, 3: 55-63. 10.1038/nrc967.CrossRefPubMed
5.
Milne AN, Carneiro F, O’Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet. 2009, 126: 615-628. 10.1007/s00439-009-0722-x.PubMedCentralCrossRefPubMed
6.
7.
Muers M: RNA: Genome-wide views of long non-coding RNAs. Nat Rev Genet. 2011, 12: 742-10.1038/nrg3088.CrossRefPubMed
8.
Ponting CP, Oliver PL, Reik W: Evolution and functions of long noncoding RNAs. Cell. 2009, 136: 629-641. 10.1016/j.cell.2009.02.006.CrossRefPubMed
9.
Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, Chang HY: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007, 129: 1311-1323. 10.1016/j.cell.2007.05.022.PubMedCentralCrossRefPubMed
10.
Pibouin L, Villaudy J, Ferbus D, Muleris M, Prosperi MT, Remvikos Y, Goubin G: Cloning of the mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon carcinomas. Cancer Genet Cytogenet. 2002, 133: 55-60. 10.1016/S0165-4608(01)00634-3.CrossRefPubMed
11.
Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S: Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 2006, 25: 135-141. 10.1089/dna.2006.25.135.CrossRefPubMed
12.
Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007, 12: 215-229. 10.1016/j.ccr.2007.07.027.CrossRefPubMed
13.
Lin R, Maeda S, Liu C, Karin M, Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007, 26: 851-858. 10.1038/sj.onc.1209846.CrossRefPubMed
14.
Qi P, Du X: The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2013, 26: 155-165. 10.1038/modpathol.2012.160.CrossRefPubMed
15.
Grote P, Wittler L, Hendrix D, Koch F, Wahrisch S, Beisaw A, Macura K, Blass G, Kellis M, Werber M, Herrmann BG: The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell. 2013, 24: 206-214. 10.1016/j.devcel.2012.12.012.PubMedCentralCrossRefPubMed
16.
Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: Genome regulation by polycomb and trithorax proteins. Cell. 2007, 128: 735-745. 10.1016/j.cell.2007.02.009.CrossRefPubMed
17.
Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, Van Oudenaarden A, Regev A, Lander ES, Rinn JL: Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009, 106: 11667-11672. 10.1073/pnas.0904715106.PubMedCentralCrossRefPubMed
18.
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010, 464: 1071-1076. 10.1038/nature08975.PubMedCentralCrossRefPubMed
19.
Nilsson J, Helou K, Kovacs A, Bendahl PO, Bjursell G, Ferno M, Carlsson P, Kannius-Janson M: Nuclear Janus-activated kinase 2/nuclear factor 1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by repressing Forkhead box F1. Cancer Res. 2010, 70: 2020-2029. 10.1158/0008-5472.CAN-09-1677.CrossRefPubMed
20.
Chen SH, Lin CY, Lee LT, Chang GD, Lee PP, Hung CC, Kao WT, Tsai PH, Schally AV, Hwang JJ, Lee MT: Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells. Anticancer Res. 2010, 30: 4177-4186.PubMed
21.
Sen T, Dutta A, Maity G, Chatterjee A: Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways. Biochimie. 2010, 92: 1422-1434. 10.1016/j.biochi.2010.07.005.CrossRefPubMed
22.
Moroz A, Delella FK, Lacorte LM, Deffune E, Felisbino SL: Fibronectin induces MMP2 expression in human prostate cancer cells. Biochem Biophys Res Commun. 2013, 430: 1319-1321. 10.1016/j.bbrc.2012.12.031.CrossRefPubMed
23.
Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N: MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 2010, 584: 4575-4580. 10.1016/j.febslet.2010.10.008.CrossRefPubMed
24.
Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, Srivastava S: PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 2000, 97: 12216-12221. 10.1073/pnas.97.22.12216.PubMedCentralCrossRefPubMed
25.
Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, Takata R, Akamatsu S, Kawaguchi T, Morizono T, Tsunoda T, Daigo Y, Matsuda K, Kamatani N, Nakamura Y, Kubo M: Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011, 102: 245-252. 10.1111/j.1349-7006.2010.01737.x.CrossRefPubMed
26.
Stanbridge EJ: Identifying tumor suppressor genes in human colorectal cancer. Science. 1990, 247: 12-13. 10.1126/science.2403692.CrossRefPubMed
27.
28.
Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL: Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma. 2008, 8: 171-175. 10.3816/CLM.2008.n.021.CrossRefPubMed
29.
30.
Ritzenthaler JD, Han S, Roman J: Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol Biosyst. 2008, 4: 1160-1169. 10.1039/b800533h.CrossRefPubMed
31.
Wang F, Song G, Liu M, Li X, Tang H: miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. FEBS Lett. 2011, 585: 3263-3269. 10.1016/j.febslet.2011.08.052.CrossRefPubMed
32.
Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS: Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia. 2010, 12: 837-847.PubMedCentralCrossRefPubMed
33.
Dong QZ, Wang Y, Tang ZP, Fu L, Li QC, Wang ED, Wang EH: Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 2013, 182: 954-964. 10.1016/j.ajpath.2012.11.019.CrossRefPubMed
34.
Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y: Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004, 10: 634-640. 10.1158/1078-0432.CCR-0864-02.CrossRefPubMed
35.
Qian P, Zuo Z, Wu Z, Meng X, Li G, Wu Z, Zhang W, Tan S, Pandey V, Yao Y, Wang P, Zhao L, Wang J, Wu Q, Song E, Lobie PE, Yin Z, Zhu T: Pivotal role of reduced let-7 g expression in breast cancer invasion and metastasis. Cancer Res. 2011, 71: 6463-6474. 10.1158/0008-5472.CAN-11-1322.CrossRefPubMed
36.
Menshikov M, Elizarova E, Plakida K, Timofeeva A, Khaspekov G, Beabealashvilli R, Bobik A, Tkachuk V: Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J. 2002, 367: 833-839. 10.1042/BJ20020663.PubMedCentralCrossRefPubMed
37.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW, Altman D, Balding D, Cuthill I, Dunn C, Emerson M, Hurtley S, McGrath I, Stanford C: Animal research: reporting in vivo experiments: the ARRIVE guidelines. J Gene Med. 2010, 12: 561-563. 10.1002/jgm.1473.CrossRefPubMed
38.
Sun M, Liu XH, Li JH, Yang JS, Zhang EB, Yin DD, Liu ZL, Zhou J, Ding Y, Li SQ, Wang ZX, Cao XF, De W: MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27(kip1). Mol Cancer Ther. 2012, 11: 842-852. 10.1158/1535-7163.MCT-11-1015.CrossRefPubMed
Metadata
Title
Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression
Authors
Tong-peng Xu
Ming-de Huang
Rui Xia
Xin-xin Liu
Ming Sun
Li Yin
Wen-ming Chen
Liang Han
Er-bao Zhang
Rong Kong
Wei De
Yong-qian Shu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2014
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-014-0063-7

Other articles of this Issue 1/2014

Journal of Hematology & Oncology 1/2014 Go to the issue

Case report

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia

Research

Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms

Review

Toll-like receptors in the pathogenesis of human B cell malignancies

Research

Identification of nuclear-enriched miRNAs during mouse granulopoiesis

Research

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

Reviewer acknowledgement

Journal of Hematology & Oncology reviewer acknowledgement 2013
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits